Biogen Inc (BIIB) Pops 5.63% for January 27

Equities Staff  |

One of the S&P 500’s big winners for Wednesday January 27 was Biogen Inc (BIIB) as the company’s stock climbed 5.63% to $274.50 on volume of 4.11 million shares.

The stock opened at $275.05 and saw an intraday low of $270.34 and an intraday high of $285.28. All told, the day saw a per-share gain of $14.63. The stock’s average daily volume of 2.46 million and 222.9 million shares outstanding. Biogen Inc now has a 50-day SMA is $286.80 and 200-day SMA is $331.47, and it has a 52-week high of $480.18 and a 52-week low of $254.00.

Biogen Idec Inc, is a biopharmaceutical company. The Company discovers, develops, manufactures and markets therapies for neurological, autoimmune and hematologic disorders.

Based out of Cambridge, MA, Biogen Inc has 7,550 employees and, after today’s trading, reached a market cap of $61.19 billion. Its P/S ratio is n/a, P/B ratio is 5.79, and P/FCF ratio is 39.4.

For a complete fundamental analysis analysis of Biogen Inc, check out’s Stock Valuation Analysis report for BIIB. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Level Headed at World Crypto Con - Steve Beauregard CRO Steve Beauregard joins Jack Brewer at World Crypto Con.

Emerging Growth

Invictus MD Strategies Corp

Invictus MD Strategies Corp is focused on two main verticals within the Canadian cannabis sector under the Access to Cannabis for Medical Purposes Regulations having investment in Acreage Pharms Ltd.,…